| Assessment Status | Rapid review complete |
| HTA ID | 20043 |
| Drug | Sodium hydrogen carbonate |
| Brand | Thamicarb® |
| Indication | For metabolic acidosis in chronic kidney disease. |
| Assessment Process | |
| Rapid review commissioned | 28/09/2020 |
| Rapid review completed | 23/11/2020 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that sodium hydrogen carbonate (Thamicarb®) not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.